Login
$ELUT
$0.82 +$0.00 (0.35%) Live

$ELUT SEC Filings

Filed On Filing
12 Nov 2026 Form 4: Rakin Kevin, Director

Granted 176,000 Stock Option (Right to Buy)

12 Nov 2026 Form 4: Neels Guido J, Director

Granted 117,000 Stock Option (Right to Buy)

12 Nov 2026 Form 4: Colpman David, Director

Granted 117,000 Stock Option (Right to Buy)

12 Nov 2026 Form 4: Makes Brigid, Director

Granted 117,000 Stock Option (Right to Buy)

12 Nov 2026 Form 4: Williams Michelle LeRoux, CHIEF SCIENTIFIC OFFICER

Granted 446,000 Stock Option (Right to Buy)

12 Nov 2026 Form 4: Ferguson Matthew, CHIEF FINANCIAL OFFICER

Granted 446,000 Stock Option (Right to Buy)

12 Nov 2026 Form 4: Mills C Randal, Director

Granted 895,000 Stock Option (Right to Buy)

10 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch

14 Sep 2026 Form 4: Williams Michelle LeRoux, CHIEF SCIENTIFIC OFFICER

Received 12,500 shares by exercise or conversion · Gave up 4,269 shares to cover exercise price or tax ($3.42K)

14 Sep 2026 Form 4: Ferguson Matthew, CHIEF FINANCIAL OFFICER

Received 12,500 shares by exercise or conversion · Gave up 4,486 shares to cover exercise price or tax ($3.59K)

14 Sep 2026 Form 4: Mills C Randal, Director

Received 27,083 shares by exercise or conversion · Gave up 9,718 shares to cover exercise price or tax ($7.77K)

21 Aug 2026 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

On August 17, 2026, Elutia Inc. (the “Company”) completed the previously announced sale of its Women’s Health segment (the “SimpliDerm Business”) to Cellution Biologics Inc. (“Cellution Biologics” or the “Buyer”). The sale (the “SimpliDe...

14 Aug 2026 FORM S-8
14 Aug 2026 10-Q
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 8-K: Results of Operations and Financial Condition

Funded through launch: secured up to $26 million of capital without an equity offering

11 Aug 2026 SCHEDULE 13G
07 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

20 Jul 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) THE REGISTRANT CUSTOMARILY AND ACTUALLY TR...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support